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Introduction: Contralateral lung tumors in non–small-cell lung can-
cer (NSCLC) are classiﬁed as stage M1a yet may represent hema-
togenous metastases or synchronous primary tumors. The impact of 
these tumors on overall survival (OS) is poorly understood. Here, we 
aim to determine whether NSCLC patients with M1a disease due 
only to a contralateral tumor nodule exhibit a favorable prognosis 
relative to other M1a or M1b patients.
Methods: Retrospective evaluation of the impact of contralateral 
tumor nodules on OS in NSCLC stratiﬁed by primary tumor size and 
N stage attained from Surveillance, Epidemiology, and End Results 
database.
Results: Of 173,640 patients, 5161 M1a-contra patients were identi-
ﬁed. Median and 3-year OS for these patients exceeded that of patients 
with M1b (p < 0.0001) or other M1a disease (p < 0.0001). Primary 
tumor size and N stage were strongly associated with OS in M1a-
contra patients. Three-year OS demonstrated a delayed convergence 
between M1a-contra and other M1a patients with primary tumors 
greater than or equal to 3 cm or mediastinal lymph node involvement. 
Proportional hazard modeling indicated that T1-2N0-1M1a-contra 
patients exhibit OS not signiﬁcantly different (p = 0.258) from that 
predicted with comparable T and N stage disease plus a second early-
stage primary.
Conclusions: Contralateral tumors in NSCLC carry a more favor-
able prognosis than other M1a or M1b disease. Primary tumor size 
and N stage may help distinguish M1a-contra patients with hema-
togenous metastasis from those with a synchronous, second primary.
Key Words: Non–small-cell lung cancer, Staging, Contralateral 
tumor, SBRT.
(J Thorac Oncol. 2015;10: 1608–1615)
After analyses of the International Association for the Study of Lung Cancer (IASLC) database in 2007, the 7th edition 
American Joint Committee on Cancer (AJCC) staging man-
ual classiﬁed non–small-cell lung cancer (NSCLC) patients 
with contralateral tumors as stage M1a.1 The IASLC database 
included only 230 patients with M1a disease due only to a 
contralateral tumor nodule (M1a-contra), and the recursive 
partitioning analysis used to validate the current staging sys-
tem in this database did not analyze these patients separately 
from those with other M1a disease.1 Rather than unambigu-
ous metastatic disease, we hypothesize that there are clinically 
meaningful differences in outcome among NSCLC patients 
with M1a disease limited to a contralateral pulmonary tumor 
compared with patients with other metastatic disease.
The prognosis for M1a-contra patients can be antici-
pated to be quite different depending on whether the contralat-
eral tumor is metastatic. Patients with a second primary tumor 
and no clinical evidence of metastasis are theoretically cur-
able with an expected prognosis more favorable than patients 
with metastatic disease and less favorable than patients with 
a single M0 primary because of multiplication of risk from 
independent sites. The assessment of whether a synchronous 
contralateral tumor is metastatic could have important impli-
cations for oncologic management.
When synchronous tumors are of distinct histologic sub-
types, the designation of a second primary tumor is readily 
made. Yet, more than half of synchronous contralateral NSCLC 
tumors are of the same histology as the ipsilateral primary.2 
Contemporary noninvasive methods cannot distinguish between 
a hematogenous metastasis and a second primary tumor.3 In 
this situation, some clinicians have historically relied upon the 
empiric criteria of Martini and Melamed,4 labeling as synchro-
nous primaries those tumors with no cancer in shared lymph 
node basins, no distant metastases, and no carcinoma in situ. 
Despite its longevity, this algorithm originates from an empiric 
study of only 50 patients. In this study, we use the Surveillance, 
Epidemiology, and End Results (SEER) database to identify the 
largest reported cohort to date of NSCLC patients with M1a-
contra disease, and we evaluate the prognostic correlates of 
overall survival (OS) in this population.
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PATIENTS AND METHODS
Study Population
SEER-18 registry data were used to identify patients 
meeting inclusion criteria: site = lung and bronchus, behav-
ior = malignant, age = 25 to 84 years, and year of diagno-
sis = 2004 to 2009.5 Exclusion criteria were prior malignancy 
and histology other than NSCLC (ICD 03 = 8000–8003, 
8041–8045, 8800–9989; ICD 02 = 8000, 8041, 8043, 8082, 
8094, 8130, 8144, 8145, 8170, 8247, 8263, 8290, 8333, 
8340, 8350, 8440, 8441, 8460, 8470, 8471, 8500, 8503, 
8520, 8530, 8580, 8680, 8711, 8720, 8770, 8801, 9070). 
Variables captured were year of diagnosis, sex, race, his-
tology, ICD 0–2, ICD 0–3, number of primaries, sequence 
number, collaborative stage (CS) tumor size, CS extension, 
CS lymph nodes, CS mets eval, CS reg node eval, derived 
AJCC stage, derived AJCC T, derived AJCC N, derived 
AJCC M, radiation, surgery, surgery to primary site, reason 
no cancer-directed surgery, vital status, SEER cause-speciﬁc 
death classiﬁcation, and survival time in months.
Extent of disease was determined and categorized using 
SEER site-speciﬁc variables “CS mets at dx (diagnosis),” “CS 
extension,” and “CS SSF1” with selected codes as follows: 
Metastatic/M1b = CS mets at dx “30, 32, 33, 36, 37, 40, 42, 
43, 50, 51, 52, 53, or 70”; Metastatic/Other M1a = CS mets at 
dx “15, 16, 17, 18, 20, 21, 24, 25, or 26” or CS extension “720, 
760, or 790”; Metastatic by contralateral nodule only/M1a 
(M1a-contra) = CS mets at dx “23”; Non-metastatic (M0) with 
ipsilateral pulmonary nodule = CS mets at dx “35” or CS exten-
sion = “650” or CS SSF 1 = “10–40”; M0 without additional 
pulmonary nodules = CS mets at Dx = 0. Patients with CS mets 
at dx =“75 or 99” or CS extension = “950, 980, or 999” were not 
categorized regarding extent of disease and were excluded from 
analysis. Tumor size was determined from the “CS tumor size” 
variable with codes 990–999 excluded from analysis.5
Statistical Analyses
SEER*STAT version 8.1.2 software (Surveillance 
Research Program, NCI, Bethesda, MD) was used to extract 
case-level data from the SEER database. Univariate and mul-
tivariate statistical analyses were conducted using JMP Pro 10 
(Cary, NC). The χ2 test was used for univariate evaluation of 
differences in patient characteristics and treatment modalities. 
Univariate and multivariate Cox proportional hazard analy-
ses were used to evaluate correlates of OS among patients 
with contralateral tumor nodules. OS was estimated using the 
Kaplan–Meier method, and the Mantel–Cox log-rank test was 
used to compare survival in two or more groups. For both Cox 
and Kaplan–Meier analyses, patients were censored using the 
SEER survival time and vital status variables. Kaplan–Meier 
estimates of 3-year OS were compared using a Z test. For all 
analyses, a two-sided p value less than 0.05 was regarded sta-
tistically signiﬁcant.
Modeling of a Contralateral Tumor 
as a Second Primary Site
We made the assumption that the majority of the con-
tralateral nodules would have been staged T1N0 if staged 
as a second primary. To estimate the risk of an indepen-
dent contralateral primary tumor (T1N0) when added to the 
risk of a known primary tumor of variable stage (TxNx), 
we used a proportional hazard model and compared the 
estimated hazard rate for death from any cause in the M1a 
population to that estimated for patients with a compara-
ble primary tumor alone, primary tumor plus contralateral 
tumor nodule, or primary tumor plus other metastatic dis-
ease. We set forth a model in which a survival curve “A” 
represents a low-risk primary tumor (i.e., T1N0), “B” repre-
sents a primary tumor of a given stage, and “C” represents 
M1a-contra patients with identical T and N classiﬁcation 
as in B, as coded in SEER. We then compared these with a 
hypothesized survival curve of a population with the same 
T and N classiﬁcation as B and with a second primary of 
the same prognosis as A. We then determined whether curve 
C was signiﬁcantly different from what would be expected 
from A × B. To limit confounding effects, curves A, B, and 
C were derived from patients in the SEER registry who 
underwent surgical resection for early stage disease. This 
model assumes that the treatment of the tumor in curve A is 
applied to the presumed second primary in curve C, noncan-
cer causes of mortality are not influenced by a second pri-
mary tumor, and staging procedures and coding of disease 
extent are consistent across groups. Cause-speciﬁc survival 
was used in the representation of group A, whereas OS was 
used for all other groups to avoid duplicating noncancer-
related mortality when multiplying survival curves.
We want to test the hypothesis that h
C
(t) ≟ h
A
(t) + 
h
B
(t), where h(t) is the hazard function and the index refers to 
the groups deﬁned above. Let HR
XY
 denote the hazard ratio 
h
X
(t)/h
Y
(t), then it follows immediately that this is equivalent 
to testing the relationship:
HR
CB
 ≟ HR
AB
 +1
From a univariable Cox model, each HR was estimated 
from the regression coefﬁcient, β, as HR = exp(β). Let SE() 
denote the standard error. Then we can deﬁne
SE log HR 1 log 1 exp SE
log 1 exp SE
AB AB AB
AB
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We then calculated a z statistic to test the above relation-
ship between HR
CB
 and HR
AB
:
z =
+ ( )( ) −
+( ) +
log exp
SE HR SE
AB CB
AB CB
1
1 2 2
β β
β(log ) ( )
RESULTS
The study population consisted of 173,640 SEER regis-
try patients diagnosed with NSCLC between 2004 and 2009 
with no prior history of malignancy. Patient and tumor char-
acteristics are listed in Supplementary Table 1 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A883). Patients 
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were subdivided into ﬁve mutually exclusive categories: (1) 
M0, (2) M0 with a second ipsilateral tumor, (3) M1a-contra, 
(4) other M1a, or (5) M1b. A total of 5161 patients were 
identiﬁed as M1a-contra. The percent of M1a-contra patients 
increased with age, female sex, non-white race, squamous cell 
histology, primary tumor size, and N stage.
Kaplan–Meier analysis of OS demonstrates that M1a-
contra NSCLC patients exhibit superior median and 3-year 
OS (10 mo, 14.2%) relative to patients with M1b (4 mo, 4.7%, 
log-rank p < 0.0001) or other M1a disease (5 mo, 8.6%, log-
rank p < 0.0001; Fig. 1). M1a-contra patients experience infe-
rior median and 3-year OS compared with patients with M0 
disease and a second ipsilateral tumor (17 mo, 29.2%, log-
rank p < 0.0001) or patients with M0 disease and no satellite 
tumor (30 mo, 45.8%, log-rank p < 0.0001; Fig. 1).
The distribution of speciﬁc patient and tumor characteris-
tics among M1a-contra patients are shown in Table 1. Univariate 
analyses suggest that among M1a-contra patients decreased 
OS compared with M0 patients with or without a second ipsi-
lateral tumor is associated with age greater than 70 years, male 
sex, nonadenocarcinoma histology, primary tumor size, and 
N stage greater than N1 (Table 1). On multivariable analysis, 
each of these covariates maintains signiﬁcant association with 
OS, whereas primary tumor size exhibits the largest magni-
tude of impact (Table 1). This impact of primary tumor size 
on OS mirrors that observed in M0 patients; whereas patients 
with other M1a or M1b disease show a reduced magnitude of 
impact from primary tumor size on OS (Supplementary Table 
2, Supplemental Digital Content 1, http://links.lww.com/JTO/
A883). M1a-contra patients were less likely to receive sur-
gery or radiation compared with those with M0 disease, (p < 
0.0001, Supplementary Table 3, Supplemental Digital Content 
1, http://links.lww.com/JTO/A883). Notably, with increasing 
tumor size or N stage, M1a-contra patients tended to be treated 
less frequently with surgery and more frequently with radia-
tion (Supplementary Table 4, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A883).
Kaplan–Meier analyses indicate that M1a-contra 
patients exhibit improved median survival relative to those 
with other M1a or M1b disease regardless of primary tumor 
size (Fig. 2A–E). A difference in 3-year OS is observed 
between these groups for patients with primary tumors less 
than or equal to 3 cm (Fig. 2F), but not for those with greater 
than 3 cm because of a convergence of survival curves at 
longer follow-up (Fig. 2C–F). Similarly, when stratiﬁed by 
N stage, M1a-contra patients show improved median sur-
vival compared with those with other M1a or M1b disease, 
regardless of N stage (Fig. 3A–D). This translates to a survival 
advantage at 3 years in the setting of N0 to N2 disease with the 
magnitude of this difference diminishing as N stage increases 
and becoming nonsigniﬁcant with N3 disease (Fig. 3E).
We examined the impact on survival from a contralat-
eral tumor nodule with that from contralateral or other N3 
regionally advanced lymph node involvement by comparing 
OS among patients with (1) N0-1M1a-contra or (2) N3M0 
disease. If a contralateral tumor represents metastatic disease 
the former cohort would be expected to exhibit worse sur-
vival, whereas if such a nodule is a second primary then these 
patients may exhibit more favorable survival compared with 
those with advanced nodal disease. We observe that for pri-
mary tumors less than or equal to 2 cm, M1a-contra patients 
exhibit superior median OS compared with those with N3M0 
disease (28 versus 15 mo, p = 0.0004). With increasing tumor 
size, this difference trends from superiority to inferiority 
(Fig. 4). M1a-contra and N3M0 patients with primary tumors 
measuring 2.1 to 7.0 cm exhibit similar median OS (M1a-
contra versus N3M0 stratiﬁed by T size: 2.1–3 cm, 19 ver-
sus 14 mo, p = 0.123; 3.1–5 cm, 13 versus 13 mo, p = 0.496; 
5.1–7 cm, 11 versus 12 mo, p = 0.064). For primary tumors 
measuring greater than 7 cm, M1a-contra patients experience 
diminished median OS compared with those with N3M0 dis-
ease (7 versus 9 mo, p = 0.003; Fig. 4).
We modeled the expected risk of an independent syn-
chronous primary tumor by combining the hazard to OS 
from a given primary tumor and N stage with the hazard to 
cause-speciﬁc survival from a second T1 primary tumor. This 
combined hazard was then compared with that observed for 
M1a-contra patients in the SEER database. Stratifying this 
analysis by primary tumor and N stage, we observed that 
patients with T1-2N0-1 M1a-contra exhibited OS rates not 
signiﬁcantly different from that predicted by a model of a sec-
ond independent primary tumor (p = 0.258; Fig. 5). Patients 
with more advanced T and N stages experienced OS rates 
between that estimated for a second primary and M1b/other 
M1a disease.
FIGURE 1. Overall survival (OS) of patients with non–small-
cell lung cancer (NSCLC) stratified by extent of disease. 
Patients from the Surveillance, Epidemiology, and End Results 
(SEER) database with NSCLC were subdivided as indicated 
based on extent of disease. Kaplan–Meier OS curves (solid 
lines) are shown with 95% confidence intervals (shaded; 
log-rank p < 0.0001). Intergroup comparisons demonstrate 
that M1a-contra patients exhibit improved survival compared 
with those with other M1a or M1b disease but inferior sur-
vival compared with M0 patients (p < 0.0001 for all).
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DISCUSSION
Using the SEER database, we have analyzed the larg-
est cohort reported to date of M1a-contra NSCLC patients 
(n = 5161). We observe that these patients collectively 
exhibit greater OS than those with other M1a or M1b disease 
but reduced OS compared with M0 patients (Fig. 1). In uni-
variate and multivariate analyses, we demonstrate a strong 
correlation between primary tumor size and OS in M1a-
contra patients indicating that this parameter may be used 
to deﬁne a cohort of M1a patients with favorable progno-
sis (Table 1). The strength of this effect mimics M0 disease 
and contrasts with a relatively reduced magnitude of impact 
in patients with other M1a or M1b disease (Supplementary 
Table 2, Supplemental Digital Content 1, http://links.lww.
com/JTO/A883).
Our observations support the hypothesis that isolated 
contralateral tumors in NSCLC may represent either an inde-
pendent primary tumor or a site of hematogenous metastasis. 
The implication of this hypothesis is that M1a-contra patients 
are a dichotomous group in which clinical correlates of pri-
mary tumor metastatic potential should be strongly prognos-
tic. Our observations precisely ﬁt this prediction because 
primary tumor size is among the most robust predictors of 
metastatic potential in NSCLC.6–10
We observe improved median survival for M1a-contra 
patients compared with other M1a disease, regardless of tumor 
size and N stage (Figs. 2 and 3), and this results in a survival 
advantage at 3 years for patients with small primary tumors and 
early N stage disease. This may suggest that, in this low-risk 
cohort, many M1a-contra patients present with a contralateral, 
synchronous primary tumor, and not a hematogenous metas-
tasis. In contrast, with larger primary tumor size or higher N 
stage, the survival of M1a-contra patients approaches that of 
patients with other M1a disease by 3 years. This is consistent 
with a lead time bias effect and suggests that with large primary 
tumors or advanced N stage, M1a-contra patients may present 
with a substantial risk for low-volume hematogenous spread of 
disease. These ﬁndings are further supported by our observa-
tion that patients with N0-1M1a-contra disease exhibit greater 
survival than N3M0 patients with small primary tumors, and 
that this distinction trends to equivalence and then inferiority as 
a function of increasing tumor size (Fig. 4).
A number of limitations and potential pitfalls are 
inherent to this study. The SEER database is generated 
TABLE 1. Univariate and Multivariate Cox Models of Overall Survival in Patients with M1a Disease by Contralateral Tumor
Variable No. of Patients (%)
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Age (yr)
  <49 266 (5.6) 1.000 (ref) 1.000 (ref)
  50–69 2377 (46.1) 1.046 (0.896–1.230) 0.573 1.053 (0.870–1.287) 0.602
  70–84 2518 (48.8) 1.261 (1.081–1.482) 0.0028 1.36 (1.123–1.661) 0.001
Sex
  Female 2437 (47.22) 1.000 (ref) 1.000 (ref)
  Male 2724 (52.78) 1.269 (1.188–1.355) <0.0001 1.169 (1.081–1.266) <0.0001
Race
  White 4131 (80.0) 1.000 (ref) 1.000 (ref)
  Black 647 (12.5) 1.081 (0.981–1.189) 0.114 1.037 (0.922–1.163) 0.536
  Other/unknown 383 (7.4) 0.831 (0.728–0.944) 0.004 0.758 (0.648–0.881) 0.0002
Histology
  Squamous cell (8070) 1259 (24.4) 1.000 (ref) 1.000 (ref)
  Adenocarcinoma (8140) 1590 (30.8) 0.713 (0.654–0.777) <0.0001 0.792 (0.713–0.878) < 0.0001
  Carcinoma NOS (8010) 1419 (27.5) 1.063 (0.977–1.157) 0.158 1.107 (1.002–1.223) 0.046
  Other/unknown 893 (17.3) 0.930 (0.824–1.048) 0.235 0.958 (0.828–1.106) 0.563
Primary tumor size (cm)
  ≤2 572 (14.1) 1.000 (ref) 1.000 (ref)
  2.1–3.0 692 (17.1) 1.059 (0.916–1.225) 0.442 1.042 (0.897–1.212) 0.591
  3.1–5.0 1259 (31.1) 1.420 (1.250–1.618) <0.0001 1.331 (1.165–1.523) <0.0001
  5.0–7.0 794 (19.6) 1.751 (1.528–2.010) <0.0001 1.641 (1.423–1.895) <0.0001
  >7.0 729 (18.0) 2.183 (1.903–2.509) <0.0001 1.978 (1.711–2.291) <0.0001
N stage
  N0 1485 (31.3) 1.000 (ref) 1.000 (ref)
  N1 365 (7.7) 1.077 (0.935–1.236) 0.298 1.056 (0.900–1.233) 0.4987
  N2 2013 (42.5) 1.388 (1.279–1.506) <0.0001 1.386 (1.262–1.523) <0.0001
  N3 875 (18.5) 1.387 (1.255–1.533) <0.0001 1.323 (1.175–1.487) <0.0001
HR, hazard ratio; CI, conﬁdence interval; ref, reference category; NOS, not otherwise speciﬁed.
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retrospectively, and consequently, our analyses of this data 
are subject to the influence of patient and treatment selec-
tion bias. Notably, SEER does not provide information on 
the extent or intent of treatments rendered, although it is 
clear that differences exist in the treatments rendered to 
some of the cohorts we have studied. Consequently our 
ﬁndings are confounded by treatment-related variables and 
reflect outcomes under conventional management, a mixed 
effect of biology and treatment, rather than natural history 
of disease alone. We have attempted to control for this in 
our proportional hazards model by limiting the analysis to 
patients treated with surgery. In addition, SEER does not 
provide information on the size, number, or histology of 
contralateral tumor nodules or the methodology of stag-
ing and evaluating these tumors. As a result, some SEER 
patients classiﬁed as M1a-contra may have multiple or large 
contralateral tumors. In Figure 5, we model the risk of two 
independent contralateral lung primary tumors by multiply-
ing the hazard to OS from a given primary and the hazard to 
cause-speciﬁc survival from a second T1 tumor. Therefore, 
the comparison between our proportional hazard model and 
the observed survival of M1a-contra patients may be biased 
toward inferior outcomes in the observed M1a-contra 
cohort. As a result, this analysis may offer a conservative 
estimate of T stage and N stage criteria for identifying 
M1a-contra patients warranting consideration of curative-
intent treatment. On the other hand, the lack of information 
regarding the methods employed for evaluating contralat-
eral tumor nodules raises the possibility that, in addition to 
synchronous primary tumors and hematogenous metastases, 
A
D E
F
B C
FIGURE 2. Overall survival (OS) of patients with non–small-cell lung cancer (NSCLC) grouped by primary tumor size. Patients 
were subdivided by extent of disease and grouped based on primary tumor size: (A) ≤2 cm; (B) 2.1–3 cm; (C) 3.1–5 cm; 
(D) 5.1–7 cm; (E) >7 cm. Kaplan––Meier OS curves (solid lines) are shown together with 95% confidence intervals (shaded, 
log-rank p < 0.0001 for each graph). (F) Regardless of primary tumor size, M1a-contra patients exhibit improved survival com-
pared with those with other M1a and M1b disease and inferior survival compared with M0 patients (p < 0.0001 for all except 
primary tumor >7 cm M1a-contra versus other M1a, p = 0.0033). Improved 3-year OS is observed for M1a-contra patients 
compared with other M1a patients for primary tumors ≤2 or 2.1–3 cm (p < 0.0001 each) but not for larger primaries (3–5 cm, 
p = 0.2450; 5–7 cm, p = 0.5688; >7 cm, p = 0.1018).
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contralateral tumors in some SEER patients may represent 
benign nodules. The 3% rate of M1a-contra disease that we 
observe, however, is comparable with the 5% rate reported 
in the IASLC database.11 Consequently, the evaluation 
of contralateral tumors in this data set is likely to reflect 
current standards of care, and misdiagnoses are likely an 
exception with limited impact.
Prior studies indicate that patients with synchro-
nous lung tumors experience increased survival compared 
with those with extrapulmonary metastases and suggest 
that deﬁnitive treatment approaches in these patients are 
associated with favorable outcomes.12–17 This may be par-
ticularly true in N0 patients, perhaps reflecting enrichment 
for synchronous primary tumors.18 Our ﬁndings suggest a 
critical role for primary tumor size in stratifying risk among 
M1a-contra patients. In the absence of histopathologic cat-
egorization of a contralateral tumor as a second primary 
or metastatic, such parameters are critical to guide clini-
cal decision making. Based on our modeling of risk for two 
independent primaries, we suggest that T1-2N0-1M1a-
contra patients may exhibit OS rates not signiﬁcantly dif-
ferent from that anticipated with two primary tumors and 
no other clinical evidence of metastatic disease. Taken 
together, these ﬁndings support the use of tumor size and 
N stage in the consideration of curative-intent treatment in 
patients with M1a-contra disease.
A B
C D
E
FIGURE 3. Overall survival (OS) of patients with non–small-cell lung cancer (NSCLC) grouped by N stage. Patients 
were segregated by extent of disease and grouped based on N stage: (A) N0, (B) N1, (C) N2, or (D) N3. Kaplan–Meier 
OS curves are shown (solid line) together with 95% confidence intervals (shaded) (log-rank p < 0.0001 for each graph). 
E, Regardless of N stage, M1a-contra patients exhibit improved survival compared with patients with other M1a and 
M1b disease and inferior survival compared with patients with M0 disease (p < 0.0001 for all intergroup comparisons). 
Improved median survival translates to a durable improvement in 3-year OS for M1a-contra patients compared with those 
with other M1a disease in the context of N0 to N2 disease (N0, p = < 0.0001; N1, p = 0.0143; N2, p = 0.0034) but not 
with N3 disease (p = 0.2501).
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